Adcentrx Therapeutics Inc.

Single-Patient EA Policies/Criteria Adcentrx Therapeutics (“Adcentrx”) is a biotechnology company dedicated to developing targeted protein conjugate therapies for cancers. We conduct clinical trials to evaluate the safety and efficacy of its investigational products in support of regulatory approvals by the U.S. Food and Drug Administration (FDA) and global health authorities, with the goal of making these therapies widely accessible to patients with unmet medical needs. Expanded Access (also known as compassionate use) provides investigational medicines to patients with serious or life-threatening conditions who are not eligible for clinical trials and lack alternative treatment options. At this time, Adcentrx is not offering its investigational products through Expanded Access. Our priority is to develop safe and effective therapies and make them available as quickly as possible to patients. We remain committed to evaluating expanded access as our programs progress. We encourage patients to consult with their healthcare providers and consider participation in Adcentrx’s clinical trials, which remains the most appropriate way to access our investigational therapies. For Additional Information If you have any questions about our expanded access policy, please contact Adcentrx via email at: clinicaltrials@adcentrx.com For more information on available clinical trials, please visit clinicaltrials.gov and search company, condition, or treatment. For additional information on Expanded Access, please visit Expanded Access | FDA. Adcentrx may revise this policy at any time in line with the 21st Century Cures Act.